[Suppressive therapy for genital herpes simplex virus infections].
Sugase
Motoyasu
M
Department of Obstetrics and Gynecology, Nagano Red Cross Hospital.
D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D000077595:Famciclovir; D005260:Female; D006558:Herpes Genitalis / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D008297:Male; D055502:Secondary Prevention; D018139:Simplexvirus / Q000276:immunology / Q000502:physiology; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives; D017735:Virus Latency; D014779:Virus Replication
D000914:Antibodies, Viral; D000998:Antiviral Agents; D015415:Biomarkers; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir